PTK2 and non-small cell lung carcinoma: D-PROTAC achieved over 90% degradation of FAK in KRAS mutant NSCLC A427 cells at 800 nM, surpassing defactinib in reducing cell viability, migration, and invasion, while achieving an 85% reduction in tumor growth in vivo [69].